Argenx posts 54% YoY VYVGART sales surge in Q3 2026, mixed earnings
Argenx reported third‑quarter 2026 product net sales of $1.721 billion, a 54% year‑over‑year increase driven by VYVGART. Earnings per share came in at $7.80, above the prior‑year $5.18 but slightly below consensus. The company said it will submit a supplemental Biologics License Application for VYVGART Hytrulo in IMNM by year‑end and expects Phase 3 empasiprubart data in December 2026, while FB102 is moving to Phase 3 in celiac disease.
Why it matters
The revenue beat signals strong demand for VYVGART, supporting the company’s growth outlook, but the modest EPS miss and higher operating costs may temper short‑term stock momentum. Analysts note the mixed results could influence price targets and valuation.
Key facts
- 1Product net sales were $1.721 billion in Q3 2026, up 54% YoY. stocktitan.net
- 2VYVGART sales accounted for $1.7 billion of the product net sales. stocktitan.net
- 3Earnings per share were $7.80, versus $5.18 a year earlier. seekingalpha.com
- 4Operating profit was $486 million, below analyst expectations. rttnews.com
- 5The company expects combined R&D and SG&A expenses of about $4 billion for 2026. seekingalpha.com
- 6A supplemental Biologics License Application for VYVGART Hytrulo in IMNM is on track for submission by year‑end 2026. stocktitan.net
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.